Windtree Therapeutics, Inc. Free Cash Flow

Free Cash Flow of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Free Cash Flow growth rates and interactive chart. Free cash flowis calculated as operating cash flow minus of capital expenditures. Interest payments are excluded from the generally accepted definition of free cash flow. Free cash flow is the cash flow available to all the investors in a company, including common stockholders, preferred shareholders, and lenders. Some investors prefer FCF or FCF per share over earnings and earnings per share as a measure of profitability. However, because FCF accounts for investments in property, plant, and equipment it can be lumpy over time. Free cash flow is usually used in discounted cash flow models to determine a company's intrinsic value.


Highlights and Quick Summary

  • Free Cash Flow for the quarter ending June 29, 2020 was $-7.05 Million (a 28.6% increase compared to previous quarter)
  • Year-over-year quarterly Free Cash Flow increased by 89.16%
  • Annual Free Cash Flow for 2019 was $-24.9 Million (a 57.58% increase from previous year)
  • Annual Free Cash Flow for 2018 was $-15.8 Million (a -25.14% decrease from previous year)
  • Annual Free Cash Flow for 2017 was $-21.1 Million (a -37.74% decrease from previous year)
  • Twelve month Free Cash Flow ending June 29, 2020 was $-21.9 Million (a 2.55% increase compared to previous quarter)
  • Twelve month trailing Free Cash Flow decreased by -14.07% year-over-year
Trailing Free Cash Flow for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-21.9 Million $-21.4 Million $-24.9 Million $-25.5 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Free Cash Flow of Windtree Therapeutics, Inc.

Most recent Free Cash Flowof WINT including historical data for past 10 years.

Interactive Chart of Free Cash Flow of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Free Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-7.05 $-5.48
2019 $-5.52 $-3.73 $-6.77 $-8.83 $-24.85
2018 $-6.19 $-3.28 $-3.76 $-2.55 $-15.77
2017 $-4.81 $-3.38 $-5.53 $-7.35 $-21.07
2016 $-7.03 $-8.35 $-9.14 $-9.32 $-33.84
2015 $-7.59 $-7.53 $-9.47 $-9.11 $-33.69
2014 $-10.18 $-10.63 $-10.37 $-10.78 $-41.95
2013 $-10.44 $-10.06 $-10.21 $-10.36 $-41.06
2012 $-9.11 $-9.93 $-8.8 $-5.68 $-33.52
2011 $-5.54 $-6.09 $-6.07 $-5.09 $-22.8
2010 $-5.61 $-4.97 $-7.34 $-6.46 $-24.37

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.